Serum Institute of India Pvt. is gearing up to meet the growing demand for life-saving vaccines, with expectations to double sales in the n...

The Japanese drugmaker plans to scale up the production of its dengue vaccine Qdenga through a partnership with Indian vaccine maker Biolog...

A recent study suggests that individuals previously infected with Zika may face an increased risk of developing severe dengue and requiring...

Covovax, which is our Novavax product, is proven to be the best against Omicron and Omicron sub variants. It is also the only vaccine from ...

Sanofi reported one of the sharpest falls in its global sales in the fourth quarter, owing to the decline in diabetes drug sales, a controv...

Under the agreement, Sun Pharma will provide drug molecules to NIV for testing against zika, chikungunya and dengue in model systems, the c...

The ICGEB plans a larger vaccine trial on monkeys in America; the full-fledged human trial after that could cost more than Rs 100 crore.

The Zika virus, which was declared a global threat by the World Health Organisation last week, has been rapidly spreading in South America ...

Domestic private equity fund ICICI Venture, International Finance Corp, the investment arm of World Bank, will exit their almost 10-yr inve...

An expert consultative committee of the Indian drug regulatory agency has waived a large-scale clinical trial for a dengue vaccine develope...

Sanofi Pasteur said Food and Drug Administration of Philippines has granted marketing approval to its Dengvaxia vaccine to be licensed for ...

If cleared, the step may eventually pave the way for Dengvaxia's availability via the wide government distribution system and private chann...

French co plans to bring raft of innovative products, including preventive dengue vaccine; move may improve company’s prospects over its ri...

Dengue virus is estimated to infect up to 400 million people globally each year, researchers said.

While antibody 5J7 has been found to be effective against DENV-3, the remaining two serotypes of dengue virus (DENV-2 and DENV-4) have to b...

It is a capital-intensive business where companies require upfront payments to fund R&D activities, says Dr Rajesh Jain, joint managing dir...

India may be a possible location as a global manufacturing base for vaccines business of Sanofi-Aventis Group.